Keren Osman is an Oncology physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 73 publications with 1,932 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10 E 102nd St
New York, NY 10029
Telephone
212-241-6756Registry record last updated 17 Apr 2019.
Clinical trials
- Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Sponsor: Icahn School of Medicine at Mount Sinai
- Host Dendritic Cells in Allograft Patients
Sponsor: Icahn School of Medicine at Mount Sinai
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year202521 payments$21,640openpaymentsdata.cms.gov ↗
- Pierre Fabre Pharmaceuticals, Inc.Program year20251 payment
- Celgene CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
41.2%Short-acting sulfonamides19.6%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.3%Valacyclovir100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
25.1%Kinase inhibitor11.4%Jakafi100%Part D<11 patientsProteasome Inhibitor7.5%Ninlaro100%Part D<11 patients+ 1 more class in this area
Dermatology
21.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.2%Acyclovir100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Protocol Review and Monitoring System
Icahn School of Medicine at Mount Sinai
FY2026$99,342P30CA196521 - Protocol Review and Monitoring System
Icahn School of Medicine at Mount Sinai
FY2025$99,341P30CA196521
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
Journal for ImmunoTherapy of Cancer
2024 - CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease
Clinical Lymphoma Myeloma & Leukemia
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”